| Name | Title | Contact Details |
|---|
Takeda San Francisco is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Be Biopharma is a leader in developing B cells as medicines, treating disease with the human body`s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, allogeneic, re-dosable, and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., Be Biopharma is re-imagining medicine based on the power of B cell therapy. Be Bio was founded in October 2020 by Longwood Fund with a $52 million Series A investment led by Atlas Ventures and RA Capital, joined by Alta Partners and Takeda Ventures.
Glen Research Corporation is a Sterling, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.
Marketbase is a Herndon, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.